9. Interventions for symptomatic PDA: proportion of infants receiving open‐label medical treatment.

		Comparison
		Indomethacin	Placebo/no treatment
Therapy	Indomethacin	Prolonged vs short course* 0.95, 95% CI 0.67 to 1.34; 5 RCTs, N = 431	Indomethacin vs placebo/no treatment 0.35, 95% CI 0.23 to 0.54; 6 RCTs, N = 211
			Very early treatment (≤ day 3) vs expectant management* 0.52, 95% CI 0.26 to 1.02; 1 RCT, N = 92
			Early treatment (≤ day 7) vs expectant management* 0.33, 95% CI 0.01 to 7.91; 1 RCT, N = 127
	Ibuprofen	‐	Ibuprofen IV vs placebo/no treatment* 1.20, 95% CI 0.76 to 1.90; 7 RCTs, N = 241
			Very early treatment (≤ day 3) vs expectant management* 1.06, 95% CI 0.07 to 16.26; 1 RCT, N = 72
			Early treatment (≤ day 7) vs expectant management* 0.66, 95% CI 0.27 to 1.60; 1 RCT, N = 105

CI: confidence interval;IV: intravenous; PDA: patent ductus arteriosus; RCT: randomised controlled trials; vs: versus

Reference is the listed comparison, therapy unless otherwise indicated by *

Differences between intervention and comparison provided as risk ratio (RR), unless otherwise specified.